Background-Patients with heart failure and atrial fibrillation are at higher risk of thromboembolic events than patients with heart failure alone. Yet, the use of anticoagulation therapy varies in clinical practice, especially among older patients, for whom its effectiveness is poorly understood. Methods and Results-Using clinical registry data linked to Medicare claims from 2005 to 2011, we examined outcomes of older patients hospitalized with heart failure and atrial fibrillation who newly initiated anticoagulation therapy at discharge. We used Cox proportional hazards models and inverse probability-weighted treatment estimates to adjust for selection bias. Main outcomes were mortality and readmission at 1 and 3 years. Among 5105 patients in 195 hospitals, 1623 (31.8%) started anticoagulation therapy at discharge. Treated patients had lower unadjusted rates of all-cause mortality (26.4% versus 42.8%; P<0.001) and all-cause readmission (58.4% versus 63.7%; P<0.001) at 1 year. After inverse weighting for the probability of treatment and adjustment for other discharge medications, anticoagulation therapy was associated with significantly lower 1-year mortality (hazard ratio, 0.70; 99% confidence interval, 0.59-0.82), but there was no statistically significant difference in the risk of all-cause readmission (hazard ratio, 0.89; 99% confidence interval, 0.78-1.01) or other readmission outcomes. Results were similar at 3 years. Conclusions-Initiation of anticoagulation therapy at hospital discharge was associated with improved mortality at 1 and 3 years but was not associated with improved cardiovascular readmission among older patients with heart failure and atrial fibrillation. (Circ Cardiovasc Qual Outcomes. 2014;7:670-679.)
A mong patients hospitalized for heart failure, atrial fibrillation is present in >20% 1 and is associated with greater mortality and morbidity, such as heart failure readmission, and thromboembolic events. 2 Greater risk of stroke and associated disability makes the intersection of heart failure and atrial fibrillation a major public health problem. Anticoagulation therapy reduces the risk of thromboembolic events, but its use varies. 1, 3 Previous guidelines and performance measures for atrial fibrillation considered heart failure in the context of other risk factors, and heart failure alone is an insufficient indication for anticoagulation therapy. 4, 5 In contrast, heart failure guidelines 6 and performance measures 7 recommend warfarin at hospital discharge for all patients with heart failure and atrial fibrillation without contraindications. There is also uncertainty about whether the efficacy of anticoagulation in clinical trials translates into clinical practice. Patients with heart failure are older, have greater comorbidity, and may be less adherent to treatment than clinical trial participants. [8] [9] [10] Given variations in the use of anticoagulation therapy in clinical practice and the lack of data about real-world effectiveness among patients with heart failure, we designed the Comparative Effectiveness of Therapies for Heart Failure program using a national clinical registry linked to Medicare claims to examine associations between anticoagulation therapy and long-term outcomes of older patients discharged from a heart failure hospitalization. We hypothesized that initiation of anticoagulation therapy improved long-term outcomes of older patients with heart failure and atrial fibrillation.
Methods

Data Sources
Data were from the American Heart Association/American Stroke Association Get With the Guidelines-Heart Failure registry and Medicare claims data from the US Centers for Medicare & Medicaid Services. The registry is a voluntary hospital-based registry of patients with heart failure as the primary cause of admission or who develop significant heart failure symptoms during the hospitalization. 11 The registry succeeded the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure registry. 12 Outcome Sciences, Inc (Cambridge, MA) is the data collection coordinating center for the registry. The Duke Clinical Research Institute (Durham, NC) serves as the data analysis center and has an agreement to analyze the aggregate deidentified data for research purposes.
The Medicare data consisted of research-identifiable inpatient claims and denominator files from 2005 to 2011. The inpatient files contain institutional claims for facility costs covered under Medicare Part A. They include encrypted beneficiary, physician, and hospital identifiers; admission and discharge dates; International Classification of Diseases-Ninth Revision, Clinical Modification diagnosis and procedure codes; and diagnosis-related groups. The denominator files include birthdates, sex, race/ethnicity, death dates, and information about program eligibility and enrollment. We linked the registry data and claims data using a validated method that accounts for ≈70% of patients in the registry.
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Study Cohort
We identified Medicare beneficiaries ≥65 years with a registry hospitalization linked to Medicare claims who were discharged between January 1, 2005, and December 31, 2009. We restricted the data set to patients who were enrolled in fee-for-service Medicare at discharge, were discharged alive to home, did not leave against medical advice, and were not transferred to another short-term hospital or hospice. A total of 31 780 patients met these criteria. We further restricted the population to those who had registry documentation of atrial fibrillation (ie, medical history or atrial fibrillation at presentation or during hospitalization), had ≥1 admission vital sign and laboratory test result, had documentation of an anticoagulation therapy prescription at discharge, and did not have a contraindication to anticoagulation therapy. To minimize bias from prevalent use, we excluded patients with registry documentation of receiving anticoagulation therapy before the index hospitalization. For patients with multiple hospitalizations, we selected the first as the index hospitalization. The final cohort included 5105 patients at 195 hospitals. We defined the cohort entry date as the date of discharge from the index hospitalization.
Treatment
The treatment of interest was anticoagulation therapy prescribed at discharge, as recorded in the registry. The treated group included all patients who received a prescription; the untreated group included all other patients in the study population.
Outcomes
The outcomes of interest were all-cause mortality, all-cause readmission, and readmission for bleeding, heart failure, stroke, ischemic stroke, or other cardiovascular reason. We identified deaths from the death dates in the Medicare denominator files. We defined readmission as any new nonelective inpatient claim, excluding the index hospitalization claim, transfers to or from another hospital, and admissions for rehabilitation. Bleeding readmissions were those with a primary diagnosis of bleeding ( October 1, 2007 ) that also did not meet the criteria for bleeding, heart failure, or stroke readmission. These codes have been validated or used in other similar studies. 14, 15 The follow-up periods for ascertainment of outcomes were 1 and 3 years after discharge from the index hospitalization. We determined discharge dates from the registry. We analyzed outcomes as time-to-event outcomes and calculated days to death and days to first readmission. For patients without a particular outcome, we defined a censoring date as the earliest of 3 years after discharge, the end of Medicare claims data availability (December 31, 2011), or the date the patient enrolled in a Medicare managed care plan. We treated death as a competing risk for the readmission outcomes.
Subgroups
Subgroups of interest were defined by age, sex, race, previous stroke, concurrent antiplatelet therapy, and ejection fraction, all ascertained from the registry. Reduced ejection fraction was defined as left ventricular ejection fraction <40% or moderate/severe dysfunction. Preserved ejection fraction was left ventricular ejection fraction of ≥40% or normal or mild dysfunction.
Covariates
Covariates from the registry ( 
WHAT IS KNOWN
• Patients with heart failure and atrial fibrillation are at higher risk of thromboembolic events than patients with heart failure alone.
• The use of anticoagulation therapy varies widely in clinical practice, especially in older patients for whom its effectiveness is not well understood.
WHAT THE STUDY ADDS
• Using Get With The Guidelines-Heart Failure Registry data linked with Medicare claims data, we examined the effectiveness of anticoagulation therapy in older patients hospitalized for heart failure and atrial fibrillation that has not been previously evaluated.
• New initiation of anticoagulation therapy was associated with lower all-cause mortality at 1 and 3 years, but there was no significant association with risks of other events, such as all-cause readmission or stroke.
• Results were uniform across important subgroups, including older patients, racial/ethnic minority groups, and patients with background antiplatelet therapy. (21) . These variables have independent prognostic value for modeling all-cause hospital readmission and mortality after hospitalization for heart failure.
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Statistical Analysis
We describe baseline characteristics of the study population using frequencies for categorical variables and means with SDs for continuous variables. We tested for differences between treatment groups using χ 2 tests for categorical variables and Wilcoxon tests for continuous variables.
To describe observed outcomes, we compared the unadjusted cumulative incidence of each outcome at 1 and 3 years after discharge between treatment groups. For mortality, we used the Kaplan-Meier method to estimate cumulative incidence and log-rank tests to test for differences between groups. For the readmission outcomes, we estimated cumulative incidence using the cumulative incidence function, which accounts for the competing risk of mortality, and assessed differences between groups using Gray tests.
We estimated the association between treatment and each outcome using Cox proportional hazards models. We used robust SEs in all models to account for the clustering of patients by hospital. We imputed missing values for variables with <5% missingness using the dominant value for categorical variables and the median value for continuous variables; we treated missing data as a separate category for other variables. To address confounding by observed covariates, we used an inverse probability-weighted estimator. We calculated inverse probability weights using the propensity score-the probability of a patient receiving the treatment he or she actually received conditional on observed covariates 18 -by fitting a logistic regression model with treatment as the dependent variable and the covariates described above as independent variables, except for B-type natriuretic peptide, which had a high rate of missingness. After weighting, we again compared baseline characteristics of each treatment group to check the balance between the groups. We also estimated the treatment effect after including the receipt of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, aldosterone antagonist, digoxin, diuretic, and antiplatelet (aspirin and clopidogrel) as covariates in regression models.
In addition to estimating overall treatment effects, we estimated the effects of anticoagulation therapy in prespecified subgroups by adding to the models a subgroup variable and an interaction term between the subgroup variable and the treatment indicator. We assessed whether treatment effect differed between subgroups by testing the significance of the interaction term. We estimated the treatment effect in each subgroup using model contrasts.
Because of the number of comparisons in the analysis, we report 99% confidence intervals and used α=0.01 to establish statistical significance. All P values were based on 2-sided tests. We used R version 2.6 (R Project for Statistical Computing, Vienna, Austria) to perform the cumulative incidence analyses. For all other analyses, we used SAS version 9.2 (SAS Institute Inc, Cary, NC). The Institutional Review Board of the Duke University Health System approved this study.
Results
Of the 5105 patients in the study cohort with heart failure and atrial fibrillation, and untreated with anticoagulation before admission, 1623 (31.8%) received a new prescription for anticoagulation therapy on discharge. Table 1 shows the baseline characteristics of the study population. Patients in the treated group were younger and less likely to be women. They had fewer comorbid conditions and were less likely to have a pacemaker. Patients who were prescribed anticoagulation therapy at discharge were more likely to be prescribed an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, or digoxin but were less likely to receive antiplatelet therapy. Table 2 and the Figure show the observed cumulative incidence of the study outcomes. The cumulative incidence of mortality at 1 and 3 years was significantly lower in the 
001).
Rates of readmission for heart failure, bleeding, ischemic stroke, stroke, and other cardiovascular causes were not significantly lower among treated patients. Table 3 shows the baseline characteristics of the study population after application of the inverse probability weights (Table I in the Data Supplement shows the results of the treatment selection model). After weighting, the treatment groups were well matched on demographic characteristics, medical history, comorbid conditions, vital signs, and most laboratory test results. Factors with a standardized difference >0.1 (the threshold typically considered meaningful) were B-type natriuretic peptide level and prescription of β-blockers, diuretics, and antiplatelet agents at discharge. Table 4 shows the estimated associations between anticoagulation therapy and 1-and 3-year outcomes. After inverse weighting for the probability of treatment, the hazard of mortality was significantly lower in the treated group at both 1 and 3 years. The hazard of all-cause readmission approached significance at 1 year but not at 3 years. The differences in the hazards of readmission for heart failure, ischemic stroke, stroke, bleeding, and other cardiovascular causes were not statistically significant. After further adjustment for prescription of other medications at discharge, treated patients had lower hazards of all-cause mortality, but the hazard of all-cause readmission was not statistically significant.
After adjustment for baseline differences, results for each end point at 1 year were generally similar across subgroups (Table II in the Data Supplement). The only interaction between anticoagulation therapy and a subgroup that was modestly significant was for the outcome of all-cause readmission, where treatment had a stronger association with lower all-cause readmission in unadjusted analyses among black patients (hazard ratio, 0.63) when compared with patients of other races (hazard ratio, 0.82). After adjustment for treatment selection, this interaction was not statistically significant. Results were also similar across subgroups at 3 years (Table III in the Data Supplement). After adjustment for treatment selection, the only significant interaction between anticoagulation therapy and a subgroup was for the outcome of ischemic stroke, where treatment had a stronger association with lower stroke rates among men than among women (hazard ratio, 0.33 versus 1.01).
Discussion
Using a large registry of patients hospitalized with heart failure, we examined the clinical effectiveness of warfarin newly initiated at discharge among patients with atrial fibrillation. Overall, new initiation of anticoagulation therapy was low. Anticoagulation therapy was associated with a lower risk of 1-and 3-year mortality after adjustment for treatment selection, baseline characteristics, and prescription of other medications. Although we observed nominal associations between anticoagulation therapy and lower risks of all-cause readmission and stroke, these results did not reach the prespecified level of statistical significance.
Heart failure is commonly associated with poor outcomes in patients with atrial fibrillation, but little is known about the effectiveness of warfarin in this population. In addition, patients hospitalized for heart failure and atrial fibrillation are at high risk of thromboembolic events from hospitalization to soon after discharge. Given how frequently heart failure and atrial fibrillation coexist, there is increasing interest in how clinical trial results translate into clinical practice and to what extent benefits are observed in understudied populations. We observed a mortality rate >40% at 1 year and ≈70% by 3 years among untreated patients with heart failure and atrial fibrillation. Given the overall mortality risk among older patients with heart failure, our finding of lower risk with anticoagulation therapy deserves further study, especially with the emergence of warfarin alternatives that may be easier to administer. Our analysis included all patients with heart failure regardless of ejection fraction or other commonly excluded subgroups, and the lower mortality risk was consistent across subgroups. The association of anticoagulation therapy with lower mortality risk after adjustment for treatment selection and baseline characteristics suggests that anticoagulation therapy is effective in clinical settings among patients discharged from a heart failure hospitalization.
A common goal of effectiveness studies is to fill the evidence gap for understudied populations, such as older adults, women, racial/ethnic minority groups, and patients at high risk for poor outcomes. In heart failure and atrial fibrillation, treatment mismatch with the risks of mortality and morbidity is common. 1, 19 Our study addresses this gap and shows that anticoagulation therapy was consistently associated with lower mortality among older patients, patients with reduced left ventricular ejection fraction, and patients with a history of stroke.
Another outcome of interest is the role of anticoagulation therapy in reducing heart failure readmissions. Heart failure is associated with hypercoagulability, and worsening heart failure may be caused by unrecognized atherothrombotic events. 20, 21 Although 1-year all-cause readmission was lower among patients receiving anticoagulation therapy, heart failure readmission was not significantly lower. Reasons for readmission are complex and may not be easy targets for pharmacotherapy, especially with heart failure, in which socioeconomic factors play a role. 22 Nevertheless, the role of anticoagulation therapy in reducing the progression of heart failure remains an area of interest, and additional studies will likely need to focus on prevention of major cardiovascular events rather than readmission alone. Surprisingly, anticoagulation therapy was not associated with readmission for stroke or bleeding. For both outcomes, the number of events at 1 year was small and the mortality rate was high. Older patients with heart failure may have multiple competing risks, so it is difficult to evaluate nonfatal outcomes, such as stroke, that generally occur at low rates during a 1-year period. Clinical trials of anticoagulation therapy for atrial fibrillation have also involved a low number of stroke events, but the relative risk of mortality in these settings is lower, making the competing risk less important. These trials are also designed to observe differences for longer exposure periods. Nevertheless, the estimate for reduction in stroke readmissions favored a reduction in risk but did not reach our prespecified level of statistical significance. A notable difference between the nonfatal outcomes in our study compared with clinical trials was the requirement for a hospitalization. Hospitalization is likely associated with greater severity of both stroke and bleeding episodes than what may be reported in a clinical trial.
Other studies have examined the effectiveness of anticoagulation therapy with warfarin but not specifically in patients with heart failure. In a large ambulatory cohort of patients with nonvalvular atrial fibrillation in a managed care setting, warfarin was associated with a 51% reduction in the risk of ischemic stroke. 23 The investigators also observed a ≈30% reduction in mortality after adjustment for differences in age, sex, and known risk factors for stroke.
Our study has limitations. Despite using best practices for comparative effectiveness research, including a priori specification of objectives and design, independent review of the study design, propensity techniques, and an inception cohort, we could not eliminate the possibility of selection bias and residual confounding. Although the treatment groups were generally comparable after inverse propensity score weighting, differences remained in B-type natriuretic peptide level and the prescription of discharge medications. In addition, several clinical variables that are likely to be associated with the use anticoagulation therapy and clinical outcomes were not available, including New York Heart Association functional classification, symptom severity, frailty, use of amiodarone. Outpatient medication data were also not available, and some patients may have discontinued warfarin or been nonadherent to therapy, limiting our ability to understand time in therapeutic range. However, warfarin persistence rates are highest among older patients and patients with heart CI indicates confidence interval; and HR, hazard ratio. *From Cox proportional hazards models comparing anticoagulation therapy at discharge with no anticoagulation therapy at discharge. †After adjustment for prescription of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, aldosterone antagonist, digoxin, diuretic, and antiplatelet therapy (aspirin and clopidogrel).
‡Subcategorization of cardiovascular readmission is based on the first readmission.
failure. 24, 25 Also, we could not account for socioeconomic status, education level, and health literacy. The population consisted of older patients enrolled in fee-for-service Medicare, so the findings may not be generalizable to all patients with heart failure and atrial fibrillation. Although we observed a lower risk of mortality after adjustment for other factors associated with anticoagulation therapy, we were unable to determine cause of death because of limitations of using administrative claims data. Also, the study had a high rate of patients with preserved ejection fraction. Additional studies will be needed to evaluate further whether patients with heart failure and reduced ejection fraction have different results. Finally, the registry is a voluntary quality-improvement program, and participating hospitals may not be representative of all hospitals in the United States.
Conclusions
In older patients hospitalized for heart failure and atrial fibrillation, new initiation of anticoagulation therapy was associated with lower all-cause mortality. However, there was no significant association with risks of other events, such as all-cause readmission or stroke. Results were also uniform across important subgroups, such as older patients, racial/ethnic minority groups, and patients with background antiplatelet therapy. Because new anticoagulants are more commonly used in clinical practice, additional studies should evaluate whether the efficacy demonstrated in clinical trials translates into clinical practice.
